enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

3. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

4. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3]

5. List of GSK plc products - Wikipedia

   en.wikipedia.org/wiki/List_of_GSK_plc_products

   Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) Treximet (sumatriptan and naproxen sodium) Trimovate (clobetasone butyrate) Ultiva (remifentanil hydrochloride) Valtrex (valaciclovir hydrochloride) Ventolin (salbutamol sulfate) Ventolin Expectorant (salbutamol sulfate/guaifenesin) Ventolin HFA (albuterol)

6. Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

   www.aol.com/news/glaxo-innoviva-file-approval...

   Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

7. Analysis-Ozempic on Wall Street's list for 2027 ... - AOL

   www.aol.com/news/analysis-ozempic-wall-streets...

   Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts are betting on a 2027 list that will include Novo Nordisk's blockbuster ...

8. GSK's Trelegy Ellipta meets key goal in late-stage ... - AOL

   www.aol.com/news/gsks-trelegy-ellipta-meets-key...

   British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines ...

9. United States v. GlaxoSmithKline - Wikipedia

   en.wikipedia.org/wiki/United_States_v...

   GlaxoSmithKline was a case before the United States District Court for the Eastern District of Pennsylvania. Robert J. Merena was one of the first who filed claims against SmithKline Beecham Clinical Laboratories on November 12, 1993.